Mesalazina Sandoz (Mesalazine)

Mesalazine acts locally in the gut by blocking cyclooxygenase and lipoxygenase enzymes, which lowers prostaglandin and leukotriene production. It also modulates cytokine release and stabilises mucosal cells, resulting in decreased inflammation and promotion of healing in the intestinal lining.

The appropriate dose of Mesalazina Sandoz is determined by the prescribing clinician based on the patient’s disease severity, location, and response to therapy. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without deviation.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mesalazina Sandoz delivers mesalazine directly, whereas sulfasalazine combines mesalazine with sulfapyridine, which can cause additional side effects. Compared with other 5‑ASA formulations, mesalazine often has a more favorable tolerability profile and does not require bacterial activation in the colon.

Store Mesalazina Sandoz at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mesalazina Sandoz is taken orally, usually with a glass of water. It may be swallowed with or without food, depending on the prescriber’s advice. The tablets or granules should be taken exactly as directed to maintain consistent drug levels in the intestine.

Serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome, liver toxicity, interstitial nephritis, blood dyscrasias (e.g., leukopenia, thrombocytopenia), pancreatitis, and anaphylaxis. Patients should seek immediate medical attention if they experience rash, jaundice, unexplained fever, or worsening renal function.

Mesalazina Sandoz is contraindicated in patients with known hypersensitivity to mesalazine or any component of the formulation. It should also be avoided in individuals with severe renal or hepatic impairment unless closely monitored, and in those who have experienced serious adverse reactions to other 5‑ASA agents.